Reported Tuberculosis in the United States, 2020

Return to Main Menu

Table 45. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility Results, by Resistance to Isoniazid or Multidrug Resistance: Reporting Areas, 2020

Table 45. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility Results, by Resistance to Isoniazid or Multidrug Resistance: Reporting Areas, 2018
Reporting Area Total Culture-Positive Cases Cases with Initial Drug-Susceptibility Testing Performed1 Resistance2
Isoniazid1 Isoniazid and Rifampin1
No. (%) No. (%) No. (%)
United States 5,703 5,504 (96.5) 456 (8.3) 56 (1.0)
Alabama 61 53 (86.9) 1 (1.9) 0 (0.0)
Alaska 43 43 (100.0) 1 (2.3) 1 (2.3)
Arizona 108 107 (99.1) 6 (5.6) 0 (0.0)
Arkansas 47 46 (97.9) 0 (0.0) 0 (0.0)
California 1,376 1,340 (97.4) 142 (10.6) 11 (0.8)
Colorado 35 34 (97.1) 2 (5.9) 0 (0.0)
Connecticut 44 42 (95.5) 7 (16.7) 2 (4.8)
Delaware 14 14 (100.0) 1 (7.1) 0 (0.0)
District of Columbia 15 15 (100.0) 2 (13.3) 0 (0.0)
Florida 350 341 (97.4) 29 (8.5) 2 (0.6)
Georgia 180 165 (91.7) 16 (9.7) 1 (0.6)
Hawaii 74 73 (98.6) 5 (6.8) 2 (2.7)
Idaho 8 8 (100.0) 1 (12.5) 0 (0.0)
Illinois 157 150 (95.5) 12 (8.0) 1 (0.7)
Indiana 72 70 (97.2) 4 (5.7) 1 (1.4)
Iowa 28 28 (100.0) 1 (3.6) 0 (0.0)
Kansas 34 32 (94.1) 0 (0.0) 0 (0.0)
Kentucky 51 51 (100.0) 3 (5.9) 2 (3.9)
Louisiana 76 73 (96.1) 5 (6.8) 1 (1.4)
Maine 16 16 (100.0) 0 (0.0) 0 (0.0)
Maryland 116 111 (95.7) 13 (11.7) 2 (1.8)
Massachusetts 114 113 (99.1) 11 (9.7) 3 (2.7)
Michigan 68 68 (100.0) 9 (13.2) 0 (0.0)
Minnesota 90 89 (98.9) 10 (11.2) 3 (3.4)
Mississippi 30 29 (96.7) 2 (6.9) 0 (0.0)
Missouri 60 59 (98.3) 3 (5.1) 2 (3.4)
Montana 4 4 (100.0) 1 (25.0) 0 (0.0)
Nebraska 31 25 (80.6) 1 (4.0) 0 (0.0)
Nevada 44 44 (100.0) 6 (13.6) 1 (2.3)
New Hampshire 12 12 (100.0) 2 (16.7) 0 (0.0)
New Jersey 188 181 (96.3) 13 (7.2) 2 (1.1)
New Mexico 25 25 (100.0) 0 (0.0) 0 (0.0)
New York State3 136 124 (91.2) 13 (10.5) 1 (0.8)
New York City 365 360 (98.6) 30 (8.3) 6 (1.7)
North Carolina 135 135 (100.0) 7 (5.2) 1 (0.7)
North Dakota 10 4 (40.0) 0 (0.0) 0 (0.0)
Ohio 96 84 (87.5) 8 (9.5) 1 (1.2)
Oklahoma 49 44 (89.8) 2 (4.5) 0 (0.0)
Oregon 48 47 (97.9) 2 (4.3) 0 (0.0)
Pennsylvania 128 124 (96.9) 10 (8.1) 0 (0.0)
Rhode Island 7 7 (100.0) 0 (0.0) 0 (0.0)
South Carolina 54 54 (100.0) 6 (11.1) 1 (1.9)
South Dakota 13 13 (100.0) 0 (0.0) 0 (0.0)
Tennessee 85 82 (96.5) 5 (6.1) 0 (0.0)
Texas 684 649 (94.9) 47 (7.2) 6 (0.9)
Utah 19 19 (100.0) 1 (5.3) 0 (0.0)
Vermont 3 3 (100.0) 0 (0.0) 0 (0.0)
Virginia 127 126 (99.2) 4 (3.2) 1 (0.8)
Washington 129 125 (96.9) 9 (7.2) 1 (0.8)
West Virginia 12 12 (100.0) 0 (0.0) 0 (0.0)
Wisconsin 32 31 (96.9) 3 (9.7) 1 (3.2)
Wyoming 0 0 0 0
American Samoa4 2 2 (100.0) 0 (0.0) 0 (0.0)
Fed. States of Micronesia4 33 31 (93.9) 2 (6.5) 0 (0.0)
Guam4 41 40 (97.6) 0 (0.0) 0 (0.0)
Marshall Islands4 28 17 (60.7) 0 (0.0) 0 (0.0)
Northern Mariana Islands4 24 7 (29.2) 0 (0.0) 0 (0.0)
Puerto Rico4 23 22 (95.7) 5 (22.7) 2 (9.1)
Palau4 8 8 (100.0) 2 (25.0) 0 (0.0)
U.S. Virgin Islands4 3 0 (0.0) 0 0

1Cases with susceptibility testing complete for at least isoniazid and rifampin.
2Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia).
3Excludes New York City.
4Not included in U.S. totals.
Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.